pyrazines has been researched along with alvocidib in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blagosklonny, MV | 1 |
| Cheson, BD | 1 |
| Dai, Y; Grant, S; Rahmani, M | 1 |
| Dai, Y; Dent, P; Grant, S; Pei, XY; Rahmani, M | 1 |
| Coppola, D; Dawson, J; Doyle, A; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Kang, L; Kolla, S; Peer, C; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Shrader, E; Stuart, RK; Sullivan, DM; Talreja, N; Tombes, MB; Wellons, MD; Wright, J | 1 |
| Ohmachi, K | 1 |
| Grant, S; Holkova, B | 1 |
| Allen, JE; Aqui, N; Dicker, DT; Dolloff, NG; El-Deiry, WS; Malysz, J; Talamo, G; Vogl, D | 1 |
| Chen, S; Dai, Y; Grant, S; Jones, R; Leng, Y; Lin, H; Orlowski, RZ; Pei, XY; Zhang, Y; Zhou, L | 1 |
| Baz, RC; Bose, P; Colevas, AD; Coppola, D; Dawson, J; Doyle, LA; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Honeycutt, C; Kang, L; Kmieciak, M; Peer, CJ; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Sankala, H; Shrader, E; Stuart, RK; Sullivan, D; Tombes, MB; Wan, W; Weir-Wiggins, C; Wellons, M | 1 |
| Baum, A; Beck, J; Engelhardt, H; Gerlach, D; Gerstberger, T; Hofmann, MH; Kaya, O; Kraut, N; Popow, J; Savarese, F; Scharn, D; Schweifer, N; Tontsch-Grunt, U; Zuber, J | 1 |
3 review(s) available for pyrazines and alvocidib
| Article | Year |
|---|---|
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
Topics: Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Hematologic Neoplasms; Humans; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
2 trial(s) available for pyrazines and alvocidib
| Article | Year |
|---|---|
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Treatment Failure | 2011 |
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Drug Monitoring; Female; Flavonoids; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Retreatment; Treatment Outcome | 2014 |
6 other study(ies) available for pyrazines and alvocidib
| Article | Year |
|---|---|
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cyclosporins; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Flavonoids; Hematopoietic Stem Cells; HL-60 Cells; Humans; Jurkat Cells; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligopeptides; Paclitaxel; Piperidines; Poly(ADP-ribose) Polymerases; Pyrazines; Substrate Specificity; Thiazoles | 2001 |
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Blast Crisis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Cysteine Endopeptidases; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, Myeloid, Acute; Leupeptins; Mitogen-Activated Protein Kinases; Multienzyme Complexes; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2003 |
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Flavonoids; Fusion Proteins, bcr-abl; Humans; I-kappa B Proteins; Imatinib Mesylate; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitochondria; Mitogen-Activated Protein Kinases; NF-kappa B; Nuclear Proteins; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Piperidines; Pyrazines; Pyrimidines; RNA Polymerase II; src-Family Kinases; STAT3 Transcription Factor; STAT5 Transcription Factor; Trans-Activators | 2004 |
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Flavonoids; Humans; Mice; Multiple Myeloma; Oncogenes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidine Nucleosides; Translocation, Genetic; Treatment Outcome; Tubercidin | 2012 |
Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Cyclin T; Cyclin-Dependent Kinase 9; Cycloheximide; Flavonoids; Gene Expression Regulation; Heat-Shock Proteins; Humans; Indoles; Leupeptins; Membrane Proteins; Mice; Mice, Knockout; Mitochondrial Proteins; Piperidines; Protein Transport; Pyrazines; Pyrroles; RNA, Small Interfering; Sequestosome-1 Protein | 2014 |
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 9; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Enhancer Elements, Genetic; Flavonoids; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Piperidines; Proteins; Pyrazines; RNA Polymerase II; RNA-Binding Proteins; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2018 |